In the experimental model of colitis, BFO was found to effectively prevent colon shortening and preserve the function of the intestinal barrier, thus effectively reducing the severity of DSS‐induced colitis by maintaining barrier integrity, inhibiting increased MPO activity, attenuating splenic abnormalities, and reducing the expression and secretion of pro‐inflammatory cytokines. Here, MPO is linked to colitis.